Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Bell Potter Healthcare Conference Presentation 19 November 2026 – Melbourne, Australia: Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF) (“Neurizon” or “the Company”), a late clinical-stage biotechnology company...
Bell Potter Healthcare Conference Presentation
Filed with ASX · · 16 pages · English and French
Summary by 6ix AI
The conference will feature insights from the Chief Executive Officer, Dr. Chris Bremer, and is designed to update investors on the company's growth strategies and upcoming milestones. This filing serves to inform stakeholders about Neurizon's progress and strategic direction in the biotechnology sector.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Neurizon Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Neurizon Therapeutics
- Update - Proposed issue of securities - NUZ
- Notice of General Meeting/Proxy Form
- Prospectus
- Share Purchase Plan and Options Offer Open
- First Regimen I patient enters Active Treatment Extension
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics